Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex

Completed · Phase 3

Conditions studied: Nontuberculous Mycobacterial Infections

In brief

Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections who have failed or are intolerant of rifampin. Rifabutin may be a reasonable alternative agent in patients who fail rifampin or or intolerant of rifampin.

Key facts

Study ID

NCT03164291

Run by

The University of Texas Health Science Center at Tyler

People needed

170

Starts

1984-06-01

Expected to finish

2017-05-18

Last updated by the study team

2017-05-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults age 18 and older with positive acid-fast bacilli smears and cultures for drug-resistant mycobacteria

You may not qualify if…

• Children less than 18 years of age
• Pregnancy
• Low platelet count, except with very serious disease

Where it is running

• The University of Texas Health Science Center at Tyler — Tyler, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.